COVID Vaccination in DMT-Treated MS Patients: New Data : vim

COVID rates after vaccination are relatively low and cases mild in patients with multiple sclerosis treated with disease-modifying therapies – but vaccine antibody response is lower with anti-CD20 therapies.

Related Keywords

Florida , United States , California , Maryland , National Harbor , San Francisco , Daniel Kantor , Janice Wong , Preeti Bajaj , Rahul Dave , Bruceac Cree , Janssen Research , University Of California , Genentech , University Of Virginia College Medicine , Neuroimmunology Center , Consortium Of Multiple Sclerosis Centers , Inova Neurosciences Institute , Florida Society Of Neurology , Weill Institute For Neurosciences , Multiple Sclerosis Centers , Virginia College , Medscape Medical , Florida Society , Medical Partnership , Medscape Medical News , Weill Institute , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Vaccine , Disease Modifying Therapy , Mt , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Biologic Therapy , Immunomodulator , Lenalidomide , Receptors , Clinical Research , Clinical Trials , Linical Studies , Elderly Concerns Of Older Adults , Geriatric ,